Table 1.
Descriptive summaries of the included studies. NI = Non-Informed; UICC = Union for International Cancer Control; AJCC = American Joint Committee on Cancer; HNC = Head and Neck Cancer; OPMD = Oral Premalignant Disorders [5,7,10,14,16,20,21,26,27,37,50,57,58,61,70,71,72,73].
| Reference Number | Author | Year | Country | Sample Size | Staging Edition | Tumor Subsite | Recruitment Period | Type of Lesion | Survival Analysis |
Caspase 3/Cleaved Caspase 3 (Monoclonal) | IHC Pattern | Cut-Off Point (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | Dozic et al. [27] | 2016 | Servia | 50 | NI | Salivary Glands | 1998–2008 | HNC | OS | CPP3 (monoclonal) | cytoplasmic membrane | NI |
| 10.1016/j.archoralbio.2005.02.005. | Bascones-Ilundan et al. [50] | 2006 | Spain | 52 | NI | Oral Mucosa, Gingiva, Lip, Tongue | 1999–2003 | OPMD | UN | Active-Caspase 3 (monoclonal) | cytoplasmic membrane | 10 |
| 10.1590/1678-775720160156. | Leite et al. [21] | 2016 | Brazil | 120 | NI | Oral Cavity, Lip | NI | HNC/OPMD | UN | Cleaved Caspase 3 (polyclonal) | cytoplasmic membrane | NI |
| 10.1038/modpathol.3800398. | Oudejans et al. [37] | 2005 | Netherlands | 36 | UICC | Nasopharynges | 1995–1996 | HNC | OS | Active Caspase 3 (polyclonal) | cytoplasmic membrane | NI |
| 10.1016/j.tripleo.2010.05.070. | Mattila et al. [72] | 2010 | Finland | 66 | NI | Oral Cavity | 1991–2002 | OPMD | UN | 3CSP03 (polyclonal) | cytoplasmic membrane | NI |
| 10.1017/S0022215108002636. | Andressakis et al. [5] | 2008 | Greece | 87 | NI | Tongue | 1998–2006 | HNC | OS | 3CSP03 (polyclonal) | cytoplasmic membrane | NI |
| 10.1002/hed.21602 | Coutinho-Camillo et al. [16] | 2010 | Brazil | 229 | NI | Oral Cavity | 1970–1992 | HNC | UN | Cleaved Caspase 3 (monoclonal) | cytoplasmic membrane | NI |
| 10.1002/hed.25763 | Silva et al. [14] | 2019 | Brazil | 40 | NI | Salivary Glands | 2014–2019 | HNC | DSS, OS | Caspase 3 (monoclonal) | cytoplasmic membrane | NI |
| 10.4317/medoral.18901. | Bascones-Martínez et al. [10] | 2013 | Spain | 41 | UICC | Oral Cavity | NI | HNC | UN | Cleaved Caspase 3 (polyclonal) | cytoplasmic membrane | 25 |
| 10.1016/j.canlet.2004.11.049 | Tanimoto et al. [70] | 2005 | Japan | 57 | UICC | Oral cavity, Oropharynx, Hipopharynx | 1989–2000 | HNC | OS | Caspase 3 (monoclonal) | cytoplasmic membrane | 3 |
| 10.3892/ol.2017.6626 | Li et al. [20] | 2017 | China | 45 | NI | Oral Cavity | 2005–2007 | HNC/OPMD | UN | Caspase 3 (monoclonal) | cytoplasmic membrane | NI |
| 10.18632/oncotarget.20494. | Huang et al. [57] | 2017 | Taiwan | 185 | AJCC | Buccal Mucosa | 1993–2006 | HNC | OS, DFS, DSS | Cleaved Caspase 3 and Caspase 3 (polyclonal) | cytoplasmic membrane | 25 |
| 10.1046/j.1601-0825.2003.00998.x. | Tobón-Arroyave et al. [61] | 2004 | Colombia | 30 | NI | Oral Cavity | NI | OPMD | UN | CPP32 (monoclonal) | cytoplasmic membrane | 25 |
| 10.1371/journal.pone.0180620. | Liu et al. [71] | 2017 | Taiwan | 246 | AJCC | Tongue | 1991–2010 | HNC | DFS, DSS | Caspase 3 and Cleaved-Caspase 3 (monoclonal) | cytoplasmic membrane | 25 |
| 10.1002/path.1630 | Hague et al. [58] | 2004 | UK | 54 | NI | Tongue, Labial Mucosa, Buccal Mucosa, Palate, Floor of Mouth, Alveolar Process/Gingiva | NI | HNC/OPMD | UN | Caspase 3 and Cleaved-Caspase 3 (monoclonal) | cytoplasmic and nuclear membrane | 25 |
| 10.1097/PAI.0b013e31828a0d0c. | Poomsawat, Punyasingh and Vejchapipat [26] | 2014 | Thailand | 104 | NI | Oral Cavity | 2000–2009 | HNC/OPMD | UN | Caspase 3 AF835 (monoclonal) | cytoplasmic membrane | NI |
| 10.3233/CBM-190149. | Singh et al. [73] | 2019 | India | 20 | AJCC | Oral Cavity | NI | HNC | DFS, DSS | Caspase 3 31A1067 (monoclonal) | cytoplasmic membrane | 10 |
| 10.36740/WLek201912108 | Kovtuneko, Bakaiev and Shponka [7] | 2019 | Ukraine | 80 | AJCC | Maxillary Sinus | 2011–2016 | HNC | UN | Caspase 3 (monoclonal) | cytoplasmic membrane | NI |